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Controversy over the efficacy of many topical wound
treatments, particularly growth factors, is common,
with many clinical practitioners still confused as to the
real value of these agents. A serious lack of knowledge
appears to exist concerning the diffusion and distribu-
tion of topically applied solutes in wounds. Without
this basic understanding there seems little chance of
accurately predicting the therapeutic window of drugs
targeted at cellular activities, such as division and
chemotaxis, and processes, such as collagen lattice
deposition and contraction, occurring below the
surface of the granulating layer. This study was
designed to determine the absorption and distribution
of a number of radiolabeled solutes (water, sodium
chloride, lidocaine) and growth factors (basic fibroblast
growth factor, epidermal growth factor) applied topic-
ally to full-thickness excisional wounds in rats during
Awound effectively represents a disruption of normalskin physiology and the healing process the mechan-ism by which the body seeks to re-establish skincontinuity. The administration of topical medicationsto improve wounds has been a popular goal since the
times of the early Greeks. Recent advancements in recombinant
DNA technology and the production of large quantities of growth
factors has resulted in a dramatic escalation of interest in topical
growth factor therapy for wounds. The absorption of topically
applied solutes into and through wound sites is relatively poorly
understood. It is known that the ability of topically applied solutes
to penetrate the stratum corneum barrier of normal skin and reach
underlying tissues is determined by a number of factors, principally
those relating to (i) solute physicochemical properties and (ii) the
rate at which the local blood supply clears solutes from the tissue
into the systemic circulation (Cross and Roberts, 1993; Singh and
Roberts, 1994, 1996); however, altered absorption and distribution
in and around wound sites following topical administration remains
to be determined.
Solute absorption through a wound site is known to be much
faster than through normal skin due to the loss of the primary skin
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the early (2 d), mid (7 d), and late (12 d) stages
of repair. Results showed that water and sodium
penetrated deepest into wound sites and that changes
in water distribution and retention in the wound
paralleled the healing process. Multiple stepwise regres-
sion showed that molecular weight and tissue depth,
but not day of healing, were significant factors in
predicting the concentration of each solute in wound
and underlying tissue sites. This finding was consistent
with a tissue diffusion model developed in this study.
Basic fibroblast growth factor and epidermal growth
factor only penetrated slightly into the upper granulat-
ing layers of the wound site, and calculation of thera-
peutic doses, based on the percentage of applied solute
reaching the deeper granulating layers, is presented.
Key words: epidermal growth factor/fibroblast growth factor/
rat model/wound healing. J Invest Dermatol 112:36–41, 1999
barrier properties (Gibeault et al, 1989). As healing progresses,
however, the environment through which topically applied solutes
would be expected to diffuse is constantly changing. The healing
process is typically characterized as consisting of three continuous,
rather than discrete, phases: firstly, the inflammatory, substrate, or
lag phase; secondly, the fibroblastic, proliferative, or connective
tissue phase; and thirdly, the maturation or resorptive phase. The
types of changes occurring at the wound site include the degree
of hyperaemia and edema, the extent of neovascularization, the
cellularity, and the amount collagen and connective tissue deposition
in the granulation matrix.
If the site of action of topically applied solutes was the granulation
surface, then dosing regimens could be easily determined and
controlled through vehicle release kinetics, though the rate of
clearance from these sites may become a factor in maintaining
effective local concentrations. The site of action of most growth
factors, however, is on cells that are highly active within the deeper
layers and edges of the granulation matrix, and the concentration
of exogenously applied growth factors reaching effector cells in
these regions is vital for successful therapy. Jijon et al (1989) showed
that there are two classes of cellular receptors for epidermal growth
factor (EGF), a high-affinity population that are responsible for the
stimulation of cellular activity at low EGF concentrations, and a
second low-affinity population that is responsible for the downreg-
ulation of receptors and inhibition of cell division at high EGF
concentrations. These authors suggested that ideally local concentra-
tions of EGF should be 100–200 ng per ml. It then becomes
obvious that the dose applied to the wound surface in order to
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achieve such levels in the deeper granulation tissue is impossible
to predict without knowledge of the diffusion properties of EGF
through the wound. There is a large volume of clinical literature
examining the effects of various empiric doses and treatment
regimens of growth factors in patients with chronic ulcers and
wounds, but none examining the kinetics of that solute absorption
into the treated wounds. Not surprisingly, the results of many of
these studies were inconclusive, with nonuniform dosing to different
types of lesions at various stages of healing making comparison
between studies almost impossible. The optimal clinical concentra-
tions of topical growth factors, compounds proven to be so active
in vitro at stimulating cells involved in healing, to treat various
wound types and depths still remains to be elucidated.
This study was designed to determine and compare the absorption
and distribution of various solutes into granulating wound sites.
Two of the most popular growth factors of potential use in wound
treatment, EGF and basic fibroblast growth factor (bFGF), were
selected as model agents for this purpose. The study also aimed to
determine whether these profiles changed between applications
during early (2 d), mid (7 d), and later (12 d) periods of wound
closure in rats. Lastly, we attempted to describe findings in
terms of a wound penetration kinetic model using solute physical
properties, fraction unbound in tissue, day of healing, and tissue
depth.
MATERIALS AND METHODS
Materials Radiolabeled solutes were purchased from Amersham (Sydney,
NSW, Australia) ([125I]bFGF (human recombinant); [125I]EGF (human
recombinant); [22Na]sodium chloride) or DuPont NEN (Sydney, NSW,
Australia) ([3H]lidocaine hydrochloride, [3H]water).
Rat wound model Single 15 3 15 mm full-thickness excisional wounds
were created on the mid-left abdomen of rats, µ2 cm below the spinal
column in a manner identical to that published previously (Cross et al,
1995, 1996). Briefly, rats were anesthetized with an i.p. injection (60 mg
per kg) of sodium pentobarbitone, left abdominal hair removed with
clippers and depilatory cream, and the area swabbed with chlorhexidine
solution and dried. Wound areas were marked using a template and the
tissue excised to the level of the subcutaneous tissue using dissecting scissors
and forceps. Wounds were immediately dressed with Opsite semipermeable
transparent self-adhesive dressings, secured to the rat skin at the corners
with Supaglue adhesive. Animals were housed singly and dressings left in
place for 48 h, at which point they were removed and wounds left exposed
to the air to heal.
Wound disposition studies Animals were used in absorption studies at
2, 7, and 12 d post-wounding. Rats were anesthetized with sodium
pentobarbitone (60 mg per kg i.p., with extra doses as required during the
study period), tracings of wound sites were taken in triplicate onto
transparent acetate film and wound areas later determined using a computer-
ized digitiser. In order to prevent any absorption of solutes through the
surrounding intact skin, wounds were covered with fresh Opsite dressing
and a window cut in the dressing exposing only the area of the wound
surface. Glass diffusion cells (internal diameter 1.8 cm) were placed over
the wound site and secured with adhesive (Fig 1A). At zero time 1 ml of
phosphate buffered saline (pH 7.4) spiked with the radiolabeled solutes of
interest (µ2µCi per ml) (3H-water 1 14C-lidocaine; 125I-bFGF 1 22Na-
sodium chloride; 125I-3EGF 1 22Na-sodium chloride) was added to the
diffusion cell and allowed to diffuse into the wound site for 4 h. Blood
samples (250–300 µl) were collected from a small incision on the tail into
heparinized Capiject blood collection tubes at 60 min intervals, centrifuged
for 15 min at 13,000 3 g, and the supernatant plasma assayed for
radioactivity. A final blood sample was taken at 4 h and the rats killed
whilst still under anesthesia by cervical dislocation. The diffusion cells were
sampled and emptied using a transfer pipette and the wound surface blotted
to remove any excess solution. The abdomen was then opened and the
contents of the bladder aspirated into preweighed tubes for determination
of radioactivity excreted in the urine. Wound sites were then dissected
vertically into preweighed eppendorf tubes to give samples of wound scab,
granulation tissue matrix, subcutaneous tissue, superficial muscle, deep
muscle, and abdominal fat (Fig 1B). Tissue samples (dermis, subcutaneous
fat, superficial muscle, deep muscle, and abdominal fat) were also taken
from the contralateral side of the abdomen and assayed for radioactive
solutes to provide a measure of the extent of systemic distribution of
the solutes.
Figure 1. Diagrammatic representation of (A) an anesthetized rat during
the in vivo wound absorption study and (B) the approximate depth and
organizational structure of the various tissues dissected for determination
of solute concentration beneath the application site.
Analytical procedures Radioactivity content of 3H and 14C labeled
samples was determined by liquid scintillation counting in a 1600TR
Liquid Scintillation Analyzer (Packard, Canberra, Australia). Tissue samples
(,100 mg) were first solubilized using 1 ml NCS liquid tissue solubiliser
(Amersham) and counted following the addition of 10 ml OCS liquid
scintillation fluid (Amersham). Quench corrections were made by the
machine from programmed tissue quench curves. 125I and 22Na labeled
samples were counted using the preset channels of a gamma counter. Tissue
samples were always packed to the same height and centrifuged in 1.5 ml
tubes to normalize packing density, quench corrections were also made by
the counter software. Results were normalized and are expressed as the
percentage of applied amount of solute per gram of tissue sampled.
Data analysis When a solute is absorbed from a finite solution volume
applied to the surface of a tissue, the concentration C(h, t) at any depth h
and time t can be related to the initial concentration Co, the volume of
solution V, and the area of application A by:
–A.t.W
C(h, t) 5 Co exp ( ) exp(–Bh) (1)
V
where W is the velocity of movement of the solute in the tissue due to
diffusion or blood flow and B is a constant dependent on V and removal
of the solute to the systemic circulation by tissue blood flow. In the specific
case where movement of solute in the tissue is due to diffusion of unbound
solute, W 5 √(fu2kD) and B 5 √(k/D), where fu is the fraction of solute
unbound in the tissue, D is the diffusion coefficient of unbound solute,
and k is the rate constant for removal of unbound solute. Expressing
eqn 1 as a percentage of the applied concentration F(h, t) and taking
logarithms yields:
C(h, t) A
logF(h, t) 5 log [ ] 5 – . t.W – Bh (2)
Co V
Recognizing that D, k, and W are a function of solute size (e.g., Stokes-
Einstein equation D 5 DoMW
–α), eqn 2 can also be approximated to the
following at a given fixed time:
logF(h, t) 5 H. fu. MW–α – B.h (3)
where H, α, and B are constants.
Hence, the fraction of the applied concentration of solute at the site F
should be dependent on solute molecular weight (MW), fraction of the
solute unbound in the tissues, and depth of penetration h. F may also be
affected by the day of healing through changes in the tissue diffusivity and
blood flow. Singh and Roberts (1996) have previously used stepwise
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Figure 2. Concentration (normalized and expressed as percentage applied
dose per g wet tissue weight) of various solutes (n, sodium; s, water; u,
lidocaine; d, bFGF; j, EGF) in the wound site and underlying tissues
4 h after topical application to granulating wounds at (A) 2 d, (B) 7 d, and
(C) 12 d post-wounding in the anesthetized rat. Mean 6 SEM, n 5 3.
multiple regression to examine the effects of solute size and other solute
characteristics on tissue concentrations after dermal application. In this
work, multiple stepwise regression analysis of solute MW (water, 18;
sodium, 22; lidocaine, 234; EGF, 6000; bFGF, 17,000), fraction unbound
to albumin, tissue depth below the application site, and day of healing
were evaluated as possible determinants of tissue concentration using
Statview software on a Macintosh IISi computer.
RESULTS
The concentrations of solute determined in each wound or under-
lying tissue sample after 2, 7, and 12 d of healing are shown in
Fig 2(A–C). The average wound surface area at these time points
was 2.2, 0.68, and 0.16 cm2, respectively. Slightly increasing water
absorption into superficial granulation tissue was seen as healing
progressed and reflected the expected changes in degree of hydration
and permeability of this site. The smaller and more hydrophilic
solutes, sodium and water, penetrated most into the muscle tissue
layers below the wound site at each of the post-wounding days
tested. Their concentrations in the upper granulating layers were
lower than the larger growth factors (EGF and bFGF) and suggested
a greater diffusion through these tissues to those below. The
penetration of growth factors into the deeper tissues was poor. The
concentrations of EGF and bFGF in the collagenous granulation
tissue matrix represented only 9% and 6% (day 2), 2% and 1%
(day 7), and 2.5% and 3% (day 12) of the applied dose per g of
tissue, respectively. In the tissue immediately below the granulating
matrix, at the site of the original excision depth, the concentrations
of EGF and bFGF fell rapidly to 0.4% and 0.35%, 0.5% and 0.1%,
and 0.2% and 0.15% of the applied dose per g of tissue, respectively,
after 2, 7, and 12 d of healing.
The data obtained were analyzed using stepwise regression
analysis with the variables MW, h, and t. The regressions showed
that the logarithm of tissue concentration of solutes as a percentage
of the applied amount [logF(h,t) 5 logCss/Cv] could be significantly
related to h together with either MW or logMW of the solute,
but not to fu or t, using the following equations:
logF(h, t) 5 1.532 – 3.4 3 10–5 MW – 0.375 h (r2 5 0.80) (4)
or
logF(h, t) 5 1.98 – 0.236 logMW – 0.358 h (r2 5 0.82) (5)
Figure 3 shows the value of this regression model (using eqn 4)
in the description of wound and underlying tissue concentrations
observed experimentally for each of the solutes studied.
Plasma levels of solutes at the end of the 4 h absorption period
are shown in Fig 4(A). It can be seen that sodium had the highest
plasma levels at all post-wounding time points studied, whereas
those of the other solutes were minimal. Concentrations of solutes
in contralateral tissue samples were all below the levels determined
in the plasma. The total urinary excretion of radiolabeled solutes
is shown in Fig 4(B). The exact nature of the radiolabeled solutes
in the urine was not determined in this study and was thought to
represent the excretion of metabolites of the parent solutes. It can
be seen that the urinary excretion of sodium and water was low,
whereas that of lidocaine was relatively high and the detection of
the 125I label in the samples was similar for EGF and bFGF.
DISCUSSION
This work has shown an exponential decline in solute concentration
with tissue depth for all solutes in the wound and underlying area
unrelated to the duration of the wound repair process (Fig 2).
Such a relationship has been reported previously in normal skin
for a range of solutes (Singh and Roberts, 1996). The work also
showed that higher concentrations of the smaller solutes are found
in deeper tissues, independent of the time of repair. Singh and
Roberts (1996) reported that the diffusion of solutes into normal
tissues was related to the molecular size of the solutes. It is apparent
that the tissue diffusion dependency on size is more consistent with
diffusion through a viscous media than in solution. The free volume
model described by eqn 4 is often used in skin pharmacokinetics
to describe solute movement through pores or a mesh in which
there is a limited volume available for a solute to jump into. The
average free volume estimated from the slope in eqn 4, however,
corresponds to a solute with a molecular weight of almost 13,000.
This volume is almost 1000 times the free volume obtained for
solutes iontophoresed through human epidermis (Yoshida and
Roberts, 1992). It is apparent from eqns 4 and 5 that drug size is
an important consideration in formulating topical products to
penetrate into granulating wounds. More than 80% of the data
could be accounted for in the regressions between the tissue
concentrations, expressed as a fraction of the applied concentration,
the depth of tissue, and the size of the solute (eqns 4 and 5). The
regressions best describe the penetration of the larger ionized
solutes. The results for water showed higher concentrations in the
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Figure 3. Relationship between the tissue concentrations predicted using the model generated by stepwise regression and actual mean data observed for
each of the solutes: (A) water, (B) sodium, (C) lidocaine, (D) EGF, and (E) bFGF at 2 d (u), 7 d (s), and 12 d (n) post-wounding.
lower tissues than expected and reflect the unionized and freely
diffusible nature of this solute.
This tissue binding is most significant for polypeptides as the
slight underestimation of growth factor levels observed for the
most superficial granulation layers would be consistent with this
hypothesis. Polypeptides do not normally cross membranes and
exert their biologic activity via specific cellular receptor binding
sites on the outside of various cell populations such as fibroblasts,
keratinocytes, macrophages, and endothelial cells. Thus receptor
binding then initiate a series of biochemical events that result in
changes in cellular protein expression, activity, or growth (Hudson-
Goodman et al, 1990). The trace amounts of labeled growth factors
used in this study would also be subject to normal cellular receptor
binding in accordance with their unlabeled counterparts. The
highest population of cells expressing specific receptors for EGF
and bFGF would be present in the granulating tissue, and therefore
it is this area in which the highest level of binding of growth
factors would occur. Our analysis has also taken into account
nonspecific binding. It is known that binding normally leads to a
slowing of the diffusion process and may restrict the movement of
solutes into cells and into deeper tissues. Indeed, as shown in eqn 3
the logarithm of concentration expressed as a fraction F should be
directly related to fu. In the absence of explicit tissue binding data,
we assumed that tissue binding was directly proportional to plasma
protein binding and used the fraction of solute unbound in the
plasma, fup, as a determinant; however, the addition of this variable
did not improve the regression. Singh and Roberts (1996) also
found that fu was a significant determinant in the deeper tissue
penetration of small lipophilic solutes.
This study shows that the small hydrophilic solutes, water and
sodium, had the greatest capability to penetrate into the deeper
regions of the wound sites and into the underlying tissues. The
larger growth factors showed signs of very limited diffusion,
consistent with low fuT and high MW (eqn 3), appearing to
distribute predominantly into the upper levels of the granulating
tissue. The increased absorption of water into the granulating tissue
is consistent with increased hydration state and permeability of this
tissue. In the early stage of healing the water passes quickly through
the site as there is sufficient moisture in the wound fluid that the
water is not held and passes freely into the underlying tissues,
where it is picked up by the blood supply and distributed in the
systemic circulation. As healing progresses, the upper granulating
layer dehydrates and therefore water applied to the wound will be
trapped in hydration of the matrix. The ease with which water
penetrates into cells around the body means that its volume of
distribution would be large, as shown by the relatively low plasma
and urine levels during the study.
Sodium ions, however, although highly hydrophilic and pos-
sessing high diffusion capabilities, would be expected to have a
lower volume of distribution in the body as their diffusion from
the blood into other tissues would be limited due to the charge of
the ion. This is evidenced in this study by the higher plasma levels
of sodium detected, suggesting that the ions are not distributing
out of the systemic circulation. These ions are also not being
eliminated in the urine from the plasma due to the active reabsorp-
tion of sodium ions that constitute part of renal homeostasis.
Lidocaine does appear to be eliminated in the urine, though this
study did not determine which metabolites of the original molecule
were present in the samples measured. Lidocaine is known to
undergo fairly extensive first-pass metabolism and would be unlikely
to exist for very long in the systemic circulation in the parent form.
The rat wound model was chosen for this study based on our
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Figure 4. Comparison of (A) plasma concentrations and (B) total urinary
excretion of various solutes (n, sodium; s, water; u, lidocaine; d, bFGF;
j, EGF) after 4 h application to wound sites in anesthetized rats. Mean
6 SEM, n 5 3.
previous findings of the consistency in wound healing rates between
groups and the short duration of the healing process in these
animals. Our previous studies have shown that 15 3 15 mm
excisional full-thickness wounds in rats are usually fully healed in
around 14 d (Cross et al, 1996, 1995), allowing us to examine the
absorption of solutes into differing healing phases in animals subject
to wounds for only a relatively short period of time.
Solutes studied were delivered directly to the wound surface
from a phosphate-buffered saline vehicle in order to avoid the
complications of any component of vehicle-limited release and
subsequent availability of the different solutes to the wound site.
Gibeault et al (1989) have previously shown that the transport of
β-aminoproprionitrile into scar tissue of splinted wounds in rats
was almost twice as slow from an inert K-Y jelly vehicle as from
a saline solution. The volume of donor vehicle applied was chosen
to represent a case of infinite dose delivery with substantial amounts
of solute remaining after the 4 h study period, with the exception
of sodium and water delivered to wounds at 2 d of healing, where
Table I. Solute remaining in the vehicle above the wound
site after 4 h at each of the post-wounding time points
studied
% Applied solute remaining in donor solution
on each post-wounding study daya
Solute 2 7 12
22Na-Sodium chloride 4.0 6 1.9 60.0 6 7.6 85.8 6 2.4
3H-Water 1.1 6 0.3 40.5 6 5.5 78.8 6 14.6
14C-Lidocaine 13.1 6 3.1 33.9 6 2.4 44.0 6 7.7
125I-bFGF 83.7 6 2.0 101.7 6 1.4 98.2 6 1.6
125I-EGF 65.1 6 4.9 72.9 6 0.3 101.8 6 2.1
aData represents mean 6 SEM, n 5 3.
lower than expected tissue levels may have be found due to possible
depletion from the donor vehicle due to the rapid absorption and
distribution of these solutes (Table I).
The use of Opsite dressing to cover surrounding intact skin areas
of the wound sites complicated any measurement of rate of loss of
solute from the donor solution into the wound, as the material in
the dressing adsorbed a small amount of some solutes from the
solution (unpublished data). In the smaller wounds, however, at
day 12, when the surface area covered by dressing was the greatest,
there did not appear to be any indication of depletion of donor
solute from solutions. Therefore, it can be assumed that the tissue
levels seen at the wound sites were representative of absorption
from an infinite dose solution.
In this study we determined the plasma concentrations of
radiolabel for each of the solutes as a guide to the possible
contribution of recirculation to the tissue concentrations observed.
It can be seen that in the deeper tissues concentrations of solutes
(Fig 2) approach those observed in the plasma (Fig 4A), especially
for the growth factors, indicating that redistribution via the systemic
circulation is dominant in these tissues. It is a well-known fact that
growth factors have relatively shorter half-lives in biologic systems
and would not be expected to be present as their original form in
deeper tissues, particularly following passage through the liver. The
concentrations of bFGF and EGF observed in the more superficial
tissues, however, are in excess of plasma concentrations and
represent direct diffusion from the application site. If free radiolabel
was making a significant contribution to tissue concentrations
observed, then intermediate and deeper tissue levels should have
been much higher as the free radiolabel (125I) would have had
much higher diffusion characteristics and plasma concentrations. It
is of course realistically beyond the scope of this study to rule out
the possibility of free radiolabel contribution, a point that should
be addressed more clearly in future studies.
The data generated by this present study can be used in the
estimation of optimal therapeutic doses of topical EGF to be applied
based on the recommendations of Jijon et al (1989) of the 100–
200 ng per ml concentrations required for maximal cell stimulation
at active repair sites. To achieve these levels in superficial granulation
tissue, where concentrations of EGF measured were between 2%
and 6% of the applied dose, µ10–17 µg per ml solutions would
need to be applied depending on the stage of healing. If, however,
therapeutic doses need to be reached deeper in the granulation
matrix at the base of the healing wound, where concentrations of
0.1%–0.2% of the applied dose were detected, then topical doses
of the order of 50–100 µg per ml need to be applied. For these
doses to reflect the tissue concentrations found in this study it
would also be necessary to ensure that a sufficient volume of dose
was applied such that the drug was not depleted during absorption
periods. In a clinical study using 10 µg per ml of EGF applied
directly onto the granulating tissue of venous ulcers, Falanga et al
(1992) failed to show any significant increase in the healing response;
however, an identical dose used by Brown et al (1989) applied
directly onto 400 µm deep skin graft donor sites showed a significant
increase in the healing rate of these sites. From our results it can
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be speculated that the 10 µg per ml dose used by Falanga et al
(1992) was too low to achieve sufficient concentrations in the
deeper granulating tissue of the chronic venous ulcers, and that
only superficial layers would have received therapeutic doses,
whereas the relatively clean and extremely shallow donor graft sites
treated by Brown et al (1989) were readily accessible to the applied
dose and therapeutic levels easily reached. It is interesting to note
that the active concentration of EGF found by Brown for the
treatment of the superficial granulating tissue is identical to that
calculated from our findings (10–17 µg per ml).
The findings can similarly be applied in the calculation of topical
doses of bFGF once optimal therapeutic concentrations at the
cellular level are determined. Several studies have examined the
topical efficacy of bFGF in clinical trials and have found that the
dose levels used appear to be less critical than those reported for
EGF. Robson et al (1992) used topical doses of bFGF ranging from
1 to 1000 µg per ml in the treatment of pressure sores and found
no difference in the potentiation of healing between the dosage
forms. In studies using the diabetic mouse model of impaired
wound healing, Tsuboi and Rifkin (1990) found that a minimum
dose of 0.5 µg of bFGF was required to enhance healing, and
similarly Matuszewska et al (1994) reported that doses of 0.6 µg
and 3 µg per cm2 had equally beneficial effects in the same model.
Thus it appears that the need for determination of bFGF doses to
be applied to a wound may be more from an economical aspect,
as growth factors are notoriously expensive drugs to prescribe, than
from a physiologic point of view.
In conclusion, this study has shown that the depth of wound
tissue and the MW of topically applied solutes are significant
determinants of the distribution of that solute within granulating
wounds and underlying tissues. We have also determined that the
process of wound contracture over 12 d has no significant effect
on the permeability of the granulation matrix to the topically
applied solutes studied.
The authors gratefully acknowledge the financial support of the National Health
and Medical Research Council of Australia.
REFERENCES
Brown GL, Nanney LB, Griffen J, et al: Enhancement of wound healing by topical
treatment with epidermal growth factor. N Engl J Med 321:76–79, 1989
Cross SE, Roberts MS: Subcutaneous absorption kinetics of interferon and other
solutes. J Pharm Pharmacol 45:606–609, 1993
Cross SE, Naylor IL, Coleman RA, Teo TC: An experimental model to investigate
the dynamics of wound contraction. Br J Plast Surg 48:189–197, 1995
Cross SE, Thompson MJ, Roberts MS: The distribution of systemically administered
ampicillin, benzylpenicillin and flucloxacillin into excisional wounds in diabetic
and normal rats and the effects of local topical vasodilator treatment. Antimicrob
Agent Chemother 40:1703–1710, 1996
Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P: Topical use of
human recombinant epidermal growth factor (h-EGF) in venous ulcers.
J Dermatol Surg Oncol 18:604–606, 1992
Gibeault JD, Cravens RB, Chvapil M: Transport of β-aminoproprionitrile through
intact skin or scar tissue. J Surg Res 47:155–158, 1989
Hudson-Goodman P, Girard N, Jones MB: Wound repair and the potential use of
growth factors. Heart Lung 19:379–384, 1990
Jijon HJ, Gallup DG, Behzadian MA, Metheny WP: Assessment of epidermal growth
factor in the healing process of clean full-thickness skin wounds. Am J Obstet
Gynecol 161:1658–1662, 1989
Matuszewska B, Koegan M, Fisher DM, Soper KA, Hoe C-M, Huber AC, Bondi
JV: Acidic fibroblast growth factor: evaluation of topical formulations in a
diabetic mouse wound healing model. Pharm Res 11:65–71, 1994
Robson MC, Phillips LG, Lawrence WT, et al: The safety and effect of topically
applied recombinant basic fibroblast growth factor on the healing of chronic
pressure sores. Ann Surg 216:401–406, 1992
Singh P, Roberts MS: Effects of vasoconstriction on dermal pharmacokinetics and
local tissue distribution of compounds. J Pharm Sci 83:774–782, 1994
Singh P, Roberts MS: Local deep tissue penetration of compounds after dermal
application: Structure-tissue penetration relationships. J Pharmacol Exp Ther
279:908–917, 1997
Tsuboi R, Rifkin DB: Recombinant basic fibroblast growth factor stimulates wound
healing in healing-impaired db/db mice. J Exp Med 172:245–251, 1990
Yoshida NH, Roberts MS: Structure-transport relationships in transdermal ionto-
phoresis. Adv Drug Deliv Rev 9:239–264, 1992
